Ardelyx Q3 2026 net loss narrows 24% to $737,000
Bitget2026/11/03 21:07- Ardelyx’s third-quarter 2026 net loss narrowed 24% year-over-year to $737,000.
- Product revenue rose 19% year-over-year to $125.5 million; IBSRELA revenue climbed 23% to $96.3 million.
- The Phase 3 ACCEL trial completed enrollment ahead of schedule, with topline data expected in the second half of 2027.
- Full-year 2026 revenue guidance remained $350 million–$370 million for IBSRELA and $110 million–$120 million for XPHOZAH.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss
Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.
CoreWeave (CRWV.US) Faces Key Earnings Test: AI Cloud Debt Concerns Intensify as "Burning Cash for Growth" Model Faces Scrutiny
CoreWeave will release its third-quarter financial report. Whether it can demonstrate that its rapid revenue growth is sufficient to cover the rising financing costs and construction expenditures will directly determine the direction of market confidence.
Crypto prices
More
